Gene Therapy Products Reached to Market by 2021

Author :  

DOI : 10.29228/genediting.54101
Year-Number: 2021-2
Yayımlanma Tarihi: 2021-12-09 11:05:47.0
Language : English
Konu : MEDICINE
Number of pages: 1-21
Mendeley EndNote Alıntı Yap

Abstract

Cell and gene therapy are targeted treatments for genetic illnesses that reduce life quality and shorten lifespan. Cell and gene therapy differ from traditional treatments in that they directly target the malfunctioning gene and can cure it in a single dose. Approvals for cell and gene therapy products have increased rapidly in recent years, particularly since 2017, and investment in this sector has increased. When we look at it, cell and gene therapy products continue to be the most expensive pharmaceuticals. The high cost of R&D technologies, the length of regulatory processes, and the difficulties of mass manufacturing are some of the causes of this high cost. The cell and gene therapy product market, which was $11.9 billion in 2021, is expected to reach $43.7 billion by 2024. This target is dependent on the FDA's announcement that it expects to approve 10-20 new cell and gene therapy products per year until 2025. We have compiled a list of 25 gene therapy products that have been approved by any institution through 2021. Some of these products were withdrawn from the market after they were launched for various reasons, which we have also mentioned here.

Keywords

Abstract

Cell and gene therapy are targeted treatments for genetic illnesses that reduce life quality and shorten lifespan. Cell and gene therapy differ from traditional treatments in that they directly target the malfunctioning gene and can cure it in a single dose. Approvals for cell and gene therapy products have increased rapidly in recent years, particularly since 2017, and investment in this sector has increased. When we look at it, cell and gene therapy products continue to be the most expensive pharmaceuticals. The high cost of R&D technologies, the length of regulatory processes, and the difficulties of mass manufacturing are some of the causes of this high cost. The cell and gene therapy product market, which was $11.9 billion in 2021, is expected to reach $43.7 billion by 2024. This target is dependent on the FDA's announcement that it expects to approve 10-20 new cell and gene therapy products per year until 2025. We have compiled a list of 25 gene therapy products that have been approved by any institution through 2021. Some of these products were withdrawn from the market after they were launched for various reasons, which we have also mentioned here.

Keywords

Kaynakça

  • 1. Perry CM, Balfour JA. Fomivirsen. Drugs. 1999 Mar;57(3):375-80; discussion 381. doi: 10.2165/00003495-199957030-00010. PMID: 10193689.
  • 2. Grillone LR, Lanz R. Fomivirsen. Drugs Today (Barc). 2001 Apr;37(4):245-255. doi: 10.1358/dot.2001.37.4.620590. PMID: 12768225.
  • 3. Yazdani, A., Alirezaie, Z., Motamedi, M. J., & Amani, J. (2018). Gene therapy: A new approach in modern medicine. International Journal of Medical Reviews, 5(3), 106–117. https://doi.org/10.29252/ijmr-050304
  • effective cell and gene therapies,” press release, January 15, 2019. 5. Stein, C. A., & Castanotto, D. (2017). FDA-approved oligonucleotide therapies in 2017. Molecular Therapy, 25(5), 1069–1075.
  • 6. Usui N, Usui M. [Cytomegalovirus retinitis]. Nihon Rinsho. 1998 Jan;56(1):197-202. Japanese. PMID: 9465690.
  • 7. "CMV | Overview | Cytomegalovirus and Congenital CMV Infection | CDC".www.cdc.gov. Retrieved 202109-19
  • 8. Mulamba, G. B., Hu, A., Azad, R. F., Anderson, K. P., & Coen, D. M. (1998). Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrobial agents and chemotherapy, 42(4), 971–973. https://doi.org/10.1128/AAC.42.4.971
  • 9. Bubela T, McCabe C. Value-engineered translation: developing biotherapeutics that align with healthsystem needs. Am J Manag Care. 2014 Jul;20(10 Spec No):E3. PMID: 25830190.
  • 10. "Public Statement on Vitravene (fomivirsen): Withdrawal of the Marketing Authorization in the European Union" (PDF). EMA. August 6, 2002.
  • 11. Xia Y, Li X, Sun W. Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China. Curr Gene Ther. 2020;20(2):127-141. doi: 10.2174/1566523220999200731003206. PMID:
  • cancers. Hum Gene Ther. 2005 Sep;16(9):1016-27. doi:
  • 10.1089/hum.2005.16.1016. PMID: 16149900.
  • 13. Zhang WW, Li L, Li D, Liu J, Li X, Li W, Xu X, Zhang MJ, Chandler LA, Lin H, Hu A, Xu W, Lam DM. The First Approved Gene Therapy Product for Cancer Adp53 (Gendicine): 12 Years in the Clinic. Hum Gene Ther. 2018 Feb;29(2):160-179. doi: 10.1089/hum.2017.218. PMID: 29338444.
  • 14. Peng, Zhaohui (May 1, 2004). "The Genesis of Gendicine: The Story Behind the First Gene Therapy". Biopharm International.
  • 15. Li Y, Li B, Li CJ, Li LJ. Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors. Expert Opin Biol Ther. 2015 Mar;15(3):437-54. doi: 10.1517/14712598.2015.990882. Epub 2014 Dec 12. PMID: 25496374.
  • 16. Tobin KA. Macugen treatment for wet age-related macular degeneration. Insight. 2006 Jan-Mar;31(1):114. PMID: 16817567.
  • 17. Vinores S. A. (2006). Pegaptanib in the treatment of wet, age-related macular degeneration. International journal of nanomedicine, 1(3), 263–268.
  • 18. Lin FL, Wang PY, Chuang YF, et al. Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update. Mol Ther. 2020;28(10):2120-2138. doi:10.1016/j.ymthe.2020.06.029
  • 19. Parashar A. (2016). Aptamers in Therapeutics. Journal of clinical and diagnostic research : JCDR, 10(6), BE01– BE6. https://doi.org/10.7860/JCDR/2016/18712.7922
  • 20. Stein CA, Castanotto D. FDA-Approved Oligonucleotide Therapies in 2017. Mol Ther. 2017 May 3;25(5):1069-1075. doi: 10.1016/j.ymthe.2017.03.023. Epub 2017 Mar 31. PMID: 28366767; PMCID: PMC5417833.
  • 21. Liang M. Oncorine, the World First Oncolytic Virus Medicine and its Update in China. Curr Cancer Drug Targets. 2018;18(2):171-176. doi: 10.2174/1568009618666171129221503. PMID:
  • 22. Liang M. Clinical development of oncolytic viruses in China. Curr Pharm Biotechnol. 2012 Jul;13(9):1852-7. doi: 10.2174/138920112800958760. PMID: 21740357.
  • 23. Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., Lei, J., Li, Y., Zhang, W., Yang, C., Wu, K., Wu, Y., Ho, S., Athiviraham, A., Lee, M. J., … He, T.-C. (2017). Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the New Era of Personalized Medicine. Genes & Diseases, 4(2), 43–63. https://doi.org/10.1016/j.gendis.2017.04.001
  • 24. Buonaguro FM, Tornesello ML, Izzo F, Buonaguro L. Oncolytic virus therapies. Pharm Pat Anal. 2012 Nov;1(5):621-7. doi: 10.4155/ppa.12.65. PMID:
  • 25. Morse M. Technology evaluation: Rexin-G, Epeius Biotechnologies. Curr Opin Mol Ther. 2005 Apr;7(2):164-9. PMID: 15844625.
  • 26. Gordon EM, Hall FL. Rexin-G, a targeted genetic medicine for cancer. Expert Opin Biol Ther. 2010 May;10(5):819-32. doi: 10.1517/14712598.2010.481666. PMID: 20384524.
  • 27. Al-Shihabi, A., Chawla, S. P., Hall, F. L., & Gordon, E. M. (2018). Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy. Molecular therapy oncolytics, 11, 122–126. https://doi.org/10.1016/j.omto.2018.11.002
  • 28. Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019). Development and clinical translation of approved gene therapy products for genetic disorders. Frontiers in Genetics, 10. https://doi.org/10.3389/fgene.2019.00868
  • 29. Kim S, Federman N, Gordon EM, Hall FL, Chawla SP. Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. Mol Clin Oncol. 2017 Jun;6(6):861-865. doi: 10.3892/mco.2017.1231. Epub 2017 Apr 28. PMID: 28588778; PMCID: PMC5451875.
  • 30. Chervyakov YV, Staroverov IN, Vlasenko ON, Bozo IY, Isaev AA, Deev RV. Pyatiletnie rezul'taty lecheniya bol'nyh khronicheskoi ishemiei nizhnikh konechnostei s ispol'zovaniem gennoi terapii [Five-year results of treating patients with chronic lower limb ischaemia by means of gene engineering]. Angiol Sosud Khir. 2016;22(4):38-44. Russian. PMID: 27935878.
  • 31. Neovasculgen. English. (n.d.). Retrieved September 28, 2021, from http://eng.hsci.ru/products/neovasculgen.
  • 33. Velazquez OC. Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing. J Vasc Surg. 2007 Jun;45 Suppl A(Suppl A):A39-47. doi: 10.1016/j.jvs.2007.02.068. PMID: 17544023; PMCID: PMC2706093.
  • 35. Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020). Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharmacology & therapeutics, 207, 107453. https://doi.org/10.1016/j.pharmthera.2019.107453
  • 36. Burnett JR, Hooper AJ, Hegele RA. Familial Lipoprotein Lipase Deficiency. 1999 Oct 12 [updated 2017 Jun 22]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. PMID: 20301485.
  • 37. T.C. Ticaret Bakanlığı. (n.d.). Retrieved September 21, 2021, from https://ticaret.gov.tr/blog/ulkelerden-ticarihaberler/kanada/kanada-hukumetinden-dusukmaliyetli-gen-ve-hucre-terapisi-ilaclarinin-gelistiril
  • 38. Crowe, Kelly (17 November 2018). "The million-dollar drug". CBCNews. CBC (Canadian Broadcasting Corporation). Retrieved 21.09.2021. ‘How a Canadian medical breakthrough that was 30 years in the making became the world’s most expensive drug — and then quickly disappeared’
  • 39. Hovingh K, Besseling J, Kastelein J. Efficacy and safety of mipomersen sodium (Kynamro). Expert Opin Drug Saf. 2013 Jul;12(4):569-79. doi: 10.1517/14740338.2013.793670. Epub 2013 Apr 23. PMID: 23611600.
  • 40. Gebhard C, Huard G, Kritikou EA, Tardif JC. Apolipoprotein B antisense inhibition--update on mipomersen. Curr Pharm Des. 2013;19(17):3132-42. doi: 10.2174/13816128113199990312. PMID: 23317401.
  • 41. Wong, E., & Goldberg, T. (2014). Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. P & T : a peer-reviewed journal for formulary management, 39(2), 119–122.
  • 42. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Mipomersen. 2018 Dec 3. PMID: 29999702.
  • 43. Meral Kayıkçıoğlu. New agents in the treatment of familial hypercholesterolemia: Lomitapide vs. Mipomersen. Turk Kardiyol Dern Ars. 2014; 42(2): 47
  • 44. Greig SL. Talimogene Laherparepvec: First Global Approval. Drugs. 2016 Jan;76(1):147-54. doi: 10.1007/s40265-015-0522-7. PMID: 26620366.
  • 45. Garnock-Jones KP. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma. BioDrugs. 2016 Oct;30(5):461-468. doi: 10.1007/s40259016-0189-y. PMID: 27516203.
  • 47. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.
  • 48. Liu BL, Robinson M, Han Z-Q, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10:292-303.
  • 49. Ramezankhani R, Torabi S, Minaei N, Madani H, Rezaeiani S, Hassani SN, Gee AP, Dominici M, Silva DN, Baharvand H and Hajizadeh-Saffar E (2020) Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies. Front. Cell Dev. Biol. 8:547653. doi: 10.3389/fcell.2020.547653
  • 50. Imlygic (2017). Viralytics. Available online at: https://www.edisoninvestmentresearch.com/?ACT=18& ID=18566&LANG= (accessed April 19, 2017).
  • Diseases; 2012–. Eteplirsen. 2020 Feb 27. PMID:
  • 52. Scoto M, Finkel R, Mercuri E, Muntoni F (August 2018). "Genetic therapies for inherited neuromuscular disorders". The Lancet. Child & Adolescent Health. 2 (8): 600–609. doi:10.1016/S2352-4642(18)30140-8. PMID 30119719
  • 53. Lim, K. R., Maruyama, R., & Yokota, T. (2017). Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug design, development and therapy, 11, 533–545. https://doi.org/10.2147/DDDT.S97635
  • 54. Eteplirsen (Exondys 51) for duchenne muscular dystrophy. Med Lett Drugs Ther. 2016 Nov 7;58(1507):145-146. PMID: 27805575.
  • 55. Kole R, Krieg AM. Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev. 2015;87:104–
  • 56. Arechavala-Gomeza V, Graham IR, Popplewell LJ, et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther. 2007;18(9):798–810.
  • 57. Refusal of the marketing authorisation for exondys ... (n.d.). Retrieved September 30, 2021, from https://www.ema.europa.eu/en/documents/smopinitial/questions-answers-refusal-marketingauthorisation-exondys-eteplirsen-outcome-reexamination_en.pdf.
  • 491-504. doi:10.1358/dot.2020.56.8.3159186. PMID
  • 59. Dhillon S (Jul 2020). "Viltolarsen: first approval". Drugs. 80 (10): 1027-1031. doi:10.1007/s40265-020-01339-3. PMID 32519222
  • 60. Prakash V. Spinraza-a rare disease success story. Gene Ther. 2017 Sep;24(9):497. doi: 10.1038/gt.2017.59.
  • 61. Arkblad E, Tulinius M, Kroksmark AK, Henricsson M, Darin N. A population-based study of genotypic and phenotypic vari-ability in children with spinal muscular atrophy. Acta Paediatr. 2009;98(5):865–72
  • 62. Darras BT, Farrar MA, Mercuri E, Finkel RS, Foster R, Hughes SG, Bhan I, Farwell W, Gheuens S. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials. CNS Drugs. 2019 Sep;33(9):919-932. doi: 10.1007/s40263-01900656-w. PMID: 31420846; PMCID: PMC6776494.
  • Challenges. J Clin Med. 2020 Jul 13;9(7):2222. doi:
  • 64. Stein, C. A., & Castanotto, D. (2017). FDA-Approved Oligonucleotide Therapies in 2017. Molecular therapy : the journal of the American Society of Gene Therapy,
  • 65. BBC. (n.d.). SMA Hastalığı Nedir, tedavisi var mı? BBC News Türkçe. Retrieved October 4, 2021, from https://www.bbc.com/turkce/haberler-turkiye
  • 66. Steelandt J, Bocquet F, Cordonnier AL, De Courtivron C, Fusier I, Paubel P. Defibrotide in Severe Sinusoidal Obstruction Syndrome: Medicine and Economic Issues. Biol Blood Marrow Transplant. 2017 Feb;23(2):347-356. doi: 10.1016/j.bbmt.2016.11.020. Epub 2016 Dec 7.
  • 67. Australian Government Department of Health. Therapeutic Goods Administration. (2020, July 31). Defitelio. Therapeutic Goods Administration (TGA). Retrieved October 4, 2021, from https://www.tga.gov.au/apm-summary/defitelio.
  • 69. Commissioner, O. of the. (n.d.). FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow. U.S. Food and Drug Administration. Retrieved October 4, 2021,
  • 70. Defitelio (defibrotide sodium) for the treatment of hepatic veno-occlusive disease. Clinical trials arena. (2021, October 1). Retrieved October 4, 2021, from https://www.clinicaltrialsarena.com/projects/defiteliodefibrotide-sodium-for-the-treatment-of-hepatic-venoocclusive-disease/.
  • 71. Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018 Jun 26;2(12):14951509. doi: 10.1182/bloodadvances.2017008375. Erratum in: Blood Adv. 2018 Aug 14;2(15):1853. PMID: 29945939; PMCID: PMC6020812.
  • 72. Ducloyer JB, Le Meur G, Cronin T, Adjali O, Weber M. La thérapie génique des rétinites pigmentaires héréditaires [Gene therapy for retinitis pigmentosa]. Med Sci (Paris). 2020 Jun-Jul;36(6-7):607-615. French. doi: 10.1051/medsci/2020095. Epub 2020 Jul 2. PMID:
  • 73. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy. Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-55. PMID: 29635265.
  • 74. Keeler AM, Flotte TR. Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? Annu Rev Virol. 2019 Sep 29;6(1):601621. doi: 10.1146/annurev-virology-092818-015530. Epub 2019 Jul 5. PMID: 31283441; PMCID:
  • 75. Nidetz NF, McGee MC, Tse LV, Li C, Cong L, Li Y, Huang W. Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharmacol Ther. 2020 Mar;207:107453. doi: 10.1016/j.pharmthera.2019.107453. Epub 2019 Dec 11. PMID: 31836454; PMCID: PMC6980784.
  • 76. Commissioner, O. of the. (n.d.). FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. U.S. Food and Drug Administration. Retrieved October 7, 2021, from https://www.fda.gov/news-events/pressannouncements/fda-approves-novel-gene-therapytreat-patients-rare-form-inherited-vision-loss.
  • 77. Darrow JJ. Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discov Today. 2019 Apr;24(4):949-954. doi: 10.1016/j.drudis.2019.01.019. Epub 2019 Jan 31. PMID: 30711576.
  • 10.1080/17512433.2019.1567326. Epub 2019 Jan 18.
  • 79. Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019 Jun;18(6):421-446. doi: 10.1038/s41573019-0017-4. Erratum in: Nat Rev Drug Discov. 2019 Mar 18;: Erratum in: Nat Rev Drug Discov. 2019 Apr 24;: PMID: 30846871.
  • 80. Drug approval package: Onpattro (patisiran). accessdata.fda.gov. (n.d.). Retrieved October 7, 2021, from https://www.accessdata.fda.gov/drugsatfda_docs/nda/20 18/210922Orig1s000TOC.cfm.
  • 81. Anonymous. (2020, December 4). Onpattro. European Medicines Agency. Retrieved October 7, 2021, from R/onpattro.
  • 82. Hoy SM. Patisiran: First Global Approval. Drugs. 2018 Oct;78(15):1625-1631. doi: 10.1007/s40265-018-0983-6.
  • 84. Hoy SM. Onasemnogene Abeparvovec: First Global Approval. Drugs. 2019 Jul;79(11):1255-1262. doi: 10.1007/s40265-019-01162-5. PMID: 31270752.
  • 85. LiverTox: Clinical and Research Information on Drug- Diseases; 2012–. Onasemnogene Abeparvovec. 2020 Aug 20. PMID: 33242238.
  • 86. D'Amico, A., Mercuri, E., Tiziano, F. D., & Bertini, E. (2011). Spinal muscular atrophy. Orphanet journal of rare diseases, 6, 71. https://doi.org/10.1186/1750-11726-71
  • 87. Thanh T. Le, Vicki L. McGovern, Isaac E. Alwine, Xueyong Wang, Aurelie Massoni-Laporte, Mark M. Rich, Arthur H.M. Burghes, Temporal requirement for high SMN expression in SMA mice, Human Molecular Genetics, Volume 20, Issue 18, 15 September 2011, Pages 3578–3591, https://doi.org/10.1093/hmg/ddr275
  • 88. Foust, K., Wang, X., McGovern, V. et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28, 271–274 (2010). https://doi.org/10.1038/nbt.1610
  • Transduct Target Ther. 2020 Jun 19;5(1):101. doi:
  • 91. Honor A, Rudnick SR, Bonkovsky HL. Givosiran to treat acute porphyria. Drugs Today (Barc). 2021 Jan;57(1):47-59. doi: 10.1358/dot.2021.57.1.3230207.
  • 92. Syed YY. Givosiran: A Review in Acute Hepatic Porphyria. Drugs. 2021 May;81(7):841-848. doi: 10.1007/s40265-021-01511-3. Epub 2021 Apr 19. PMID:
  • 93. Fontanellas A, Ávila MA, Anderson KE, Deybach JC. Current and innovative emerging therapies for porphyrias with hepatic involvement. J Hepatol. 2019 Aug;71(2):422-433. doi: 10.1016/j.jhep.2019.05.003. Epub 2019 May 16. PMID: 31102718.
  • 94. FRANCISCO, E. M. (2021, October 12). Givlaari. European Medicines Agency. Retrieved November 6, R/givlaari.
  • 95. Monaco, L., & Faccio, L. (2017). Patient-driven search for rare disease therapies: the Fondazione Telethon success story and the strategy leading to Strimvelis. EMBO molecular medicine, 9(3), 289–292. https://doi.org/10.15252/emmm.201607293
  • 97. Hoggatt J. Gene Therapy for "Bubble Boy" Disease. Cell. 2016 Jul 14;166(2):263. doi: 10.1016/j.cell.2016.06.049.
  • 98. Strimvelis EPAR product information - europa. (n.d.). Retrieved October 15, 2021, from https://www.ema.europa.eu/en/documents/productinformation/strimvelis-epar-productinformation_en.pdf.
  • 99. Fabien Touzot, Salima Hacein-Bey-Abina, Alain Fischer & Marina Cavazzana (2014) Gene therapy for inherited immunodeficiency, Expert Opinion on Biological Therapy, 14:6, 789-798, DOI: 10.1517/14712598.2014.895811
  • 100. Hershfield M. Adenosine Deaminase Deficiency. 2006 Oct 3 [Updated 2017 Mar 16]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993
  • 101. European Medicines Agency (EMA/454627/2016). (2016). Zalmoxis.
  • 103. Tisagenlecleucel (Kymriah) for ALL. Med Lett Drugs Ther. 2017 Oct 23;59(1532):177-178. PMID: 29039821.
  • 104. Gök Ö, Aslan A. Kişiye Özgü Geliştirilen Antijen Reseptörü ile Hücre Tedavisi (CAR-T). Journal of the Institute of Science and Technology, (2019), 2235-2245, 9(4), DOI: 10.21597/jist.591578.
  • 105. Silverman E. Kymriah: A Sign of More Difficult Decisions To Come. Manag Care. 2018 May;27(5):17.
  • 106. Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019 Mar;34:45-55. doi: 10.1016/j.blre.2018.11.002. Epub 2018 Nov 14. PMID:
  • 107. Papadouli I, Mueller-Berghaus J, Beuneu C, Ali S, Hofner B, Petavy F, Tzogani K, Miermont A, Norga K, Kholmanskikh O, Leest T, Schuessler-Lenz M, Salmonson T, Gisselbrecht C, Garcia JL, Pignatti F. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. Oncologist. 2020 Oct;25(10):894-902. doi: 10.1634/theoncologist.2019-0646. Epub 2020 Apr 27. PMID: 32339368; PMCID: PMC7543293.
  • 108. AlDallal SM. Yescarta: A New Era for Non-Hodgkin Lymphoma Patients. Cureus. 2020 Nov 16;12(11):e11504. doi: 10.7759/cureus.11504. PMID:
  • 109. Highlights of prescribing information these highlights do ... (n.d.). Retrieved October 16, 2021, from https://www.fda.gov/media/108377/download.
  • 110. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR TCell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10. PMID:
  • 111. Choi, H. (2016). Tissuegene-C (INVOSSA TM ) induces an anti-inflammatory environment in the arthritic knee joint via macrophage polarization. Osteoarthritis and Cartilage, 24. https://doi.org/10.1016/j.joca.2016.01.600
  • 2020 Oct;28(5):1237-1252. doi: 10.1007/s10787-020-
  • 00738-y. Epub 2020 Jul 21. PMID: 32696209; PMCID:
  • 113. Kim MK, Ha CW, In Y, Cho SD, Choi ES, Ha JK, Lee JH, Yoo JD, Bin SI, Choi CH, Kyung HS, Lee MC. A Multicenter, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of a Cell and Gene Therapy in Knee Osteoarthritis Patients. Hum Gene Ther Clin Dev. 2018 Mar;29(1):48-59. doi: 10.1089/humc.2017.249. PMID: 29641281.
  • 114. Schuessler-Lenz, M., Enzmann, H., & Vamvakas, S. (2020). Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia. Clinical pharmacology and therapeutics, 107(3), 492–494. https://doi.org/10.1002/cpt.1639
  • 115. Taher AT, Bou-Fakhredin R, Kattamis A, Viprakasit V, Cappellini MD. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Rev Hematol. 2021 Oct;14(10):897-909. doi: 10.1080/17474086.2021.1977116. Epub 2021 Sep 15.
  • 116. Kansal, A. R., Reifsnider, O. S., Brand, S. B., Hawkins, N., Coughlan, A., Li, S., Cragin, L., Paramore, C., Dietz, A. C., & Caro, J. J. (2021). Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia. Journal of market access & health policy, 9(1), 1922028. https://doi.org/10.1080/20016689.2021.1922028
  • 117. DIMITROVA, E. K. (2021, October 4). Zynteglo. European Medicines Agency. Retrieved October 18, R/zynteglo.
  • 118. "Libmeldy : EPAR - Product information". 23 April 2021. Retrieved 13 October 2021.
  • 119. Mahmood et al. Metachromatic Leukodystrophy: A Case of Triplets with the Late Infantile Variant and a Systematic Review of the Literature. Journal of Child Neurology 2010, DOI: http://doi.org/10.1177/0883073809341669
  • 120. DIMITROVA, E. K. (2021, June 28). Libmeldy. European Medicines Agency. Retrieved October 12, R/libmeldy.
  • Retrieved October 12, 2021, from https://ir.orchard-
  • 122. Han, D., Xu, Z., Zhuang, Y., Ye, Z., & Qian, Q. (2021). Current Progress in CAR-T Cell Therapy for Hematological Malignancies. Journal of Cancer, 12(2), 326–334. https://doi.org/10.7150/jca.48976
  • 123. Yassine F, Sandoval-Sus J, Ayala E, Chavez J, Hamadani M, Kharfan-Dabaja MA. Cellular Therapies for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 May;27(5):363-370. doi: 10.1016/j.jtct.2021.01.026. Epub 2021 Feb 6. PMID: 33965173.
  • 124. DIMITROVA, E. K. (2021, October 15). Tecartus. R/tecartus.
  • 125. Albinger, N., Hartmann, J., & Ullrich, E. (2021). Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene therapy, 28(9), 513–527. https://doi.org/10.1038/s41434-021-00246-w
  • 126. Keam SJ. Elivaldogene Autotemcel: First Approval. Mol Diagn Ther. 2021 Aug 23. doi: 10.1007/s40291-02100555-1. Epub ahead of print. PMID: 34424497.
  • 127. BUCKINGHAM, L. (2021, July 27). Skysona. European Medicines Agency. Retrieved November 6, 2021, from R/skysona.
  • 128. Pagliarulo, N. (2021, October 21). Bluebird, winding down in Europe, withdraws another rare disease gene therapy. BioPharma Dive. Retrieved November 6, 2021, from https://www.biopharmadive.com/news/bluebirdwithdraw-gene-therapy-europe-skysona/608666/.
  • 130. Sartorius. (2021, May 4). How cdmos can digitalize their cell and gene therapy processes. Sartorius. Retrieved October 26, 2021, from https://www.sartorius.com/en/knowledge/sciencesnippets/how-cdmos-can-digitalize-their-cell-and-genetherapy-processes-751642.
MAKALE İSTATİSTİKLERİ

                                                                                                                                                                                                        

                                                                                                                                                                                                        

                                                                                                                                                                                                        
                                                                                                                                                                                                        
                                                                                                                                                                                                        

                                                                                                                                                                                                        

                                                                                                                                                                                                        



                                                                                                                                                                                                        

                                                                                                                                                                                                        
 
                                                                                                                                                                                                        
                      
                                                                                                                                                                                                        

                                                                                                                                                                                                        

                                                                                                                                                                                                        
LINKS

                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
  • 
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    

                                                                                                                                                                                                        
     Last issue
    
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    • 
                                                                                                                                                                                                        
  • 
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
         Previous issues
    
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    • 
                                                                                                                                                                                                        
  • 
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    Article Statistics
    
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    • 

                                                                                                                                                                                                        
                                                                                                                                                                                                        




                                                                                                                                                                                                        


                                                                                                                                                                                                        

                                                                                                                                                                                                        



                                                                                                                                                                                                        

                                                                                                                                                                                                        

                                                                                                                                                                                                        
Share